can IMMU-132 affect certain pathways of cancer cells when treating cancers can it ihibit the expression of TROP2

Yes, IMMU-132 (also known as sacituzumab govitecan) can affect certain pathways of cancer cells when treating cancers. It is an antibody-drug conjugate that targets the TROP2 protein, which is overexpressed in many types of cancer cells. By binding to TROP2, IMMU-132 delivers a cytotoxic drug payload directly to the cancer cells, leading to cell death.

In addition to killing cancer cells, IMMU-132 can also inhibit the expression of TROP2. This means that the drug can potentially reduce the levels of TROP2 protein in cancer cells, which may have additional therapeutic benefits. However, the exact mechanisms by which IMMU-132 affects TROP2 expression are still being studied and further research is needed to fully understand its impact on this pathway.